- Home
- COGT vs SDHC Comparison
COGT vs SDHC Comparison
Compare COGT & SDHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COGT
- SDHC
- Stock Information
- Founded
- COGT 2014
- SDHC 2008
- Country
- COGT United States
- SDHC United States
- Employees
- COGT N/A
- SDHC N/A
- Industry
- COGT Biotechnology: Pharmaceutical Preparations
- SDHC
- Sector
- COGT Health Care
- SDHC
- Exchange
- COGT Nasdaq
- SDHC Nasdaq
- Market Cap
- COGT 1.0B
- SDHC 1.2B
- IPO Year
- COGT 2018
- SDHC 2024
- Fundamental
- Price
- COGT $6.48
- SDHC $18.97
- Analyst Decision
- COGT Buy
- SDHC Hold
- Analyst Count
- COGT 7
- SDHC 4
- Target Price
- COGT $14.17
- SDHC $30.50
- AVG Volume (30 Days)
- COGT 1.0M
- SDHC 90.0K
- Earning Date
- COGT 05-06-2025
- SDHC 03-12-2025
- Dividend Yield
- COGT N/A
- SDHC N/A
- EPS Growth
- COGT N/A
- SDHC N/A
- EPS
- COGT N/A
- SDHC 1.81
- Revenue
- COGT N/A
- SDHC $975,463,000.00
- Revenue This Year
- COGT N/A
- SDHC $9.69
- Revenue Next Year
- COGT N/A
- SDHC $13.27
- P/E Ratio
- COGT N/A
- SDHC $10.50
- Revenue Growth
- COGT N/A
- SDHC 27.57
- 52 Week Low
- COGT $5.88
- SDHC $18.70
- 52 Week High
- COGT $12.61
- SDHC $39.50
- Technical
- Relative Strength Index (RSI)
- COGT 38.02
- SDHC 35.57
- Support Level
- COGT $6.31
- SDHC $18.95
- Resistance Level
- COGT $7.49
- SDHC $20.91
- Average True Range (ATR)
- COGT 0.43
- SDHC 1.28
- MACD
- COGT -0.04
- SDHC 0.06
- Stochastic Oscillator
- COGT 10.90
- SDHC 7.12
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
About SDHC Smith Douglas Homes Corp.
Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. The company has organized into five geographical segments so their reportable segments include Atlanta, Raleigh, Charlotte, Nashville, and Alabama which consists of both Birmingham and Huntsville.